Summary

The 7 major cystic fibrosis markets reached a value of US$ 10,158.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 62,492.2 Million by 2034, exhibiting a growth rate (CAGR) of 18% during 2024-2034.

The Cystic Fibrosis Market has been comprehensively analyzed in IMARC’s new report titled “Cystic Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034”. Cystic fibrosis is an inherited disorder that adversely affects the lungs, digestive system, pancreas, etc. It influences the cells that produce mucus, sweat, and digestive juices. People suffering from cystic fibrosis have defective genes that make digestive secretions thick and sticky and plug up ducts, passageways, and tubes, especially in the lungs and pancreas. The individuals who are not diagnosed until adulthood have milder diseases and experience symptoms like recurring incidences of an inflamed pancreas (pancreatitis), infertility, and pneumonia. Doctors may give drugs to open airways, thin mucus, prevent infections, and help the body get enough nutrients to fulfill its requirements. The other probable treatment options for cystic fibrosis are airway clearance techniques, vascular access devices, CFTCR modulators, surgical procedures, physical therapies, etc.

The rising prevalence of genomic mutations coupled with the increasing demand for effective medications that can treat such conditions is primarily driving the cystic fibrosis market. In addition to this, the shifting preferences of patients from intravenous therapy towards oral treatment options since they are cost-effective and less time-consuming are also propelling the market growth. Moreover, the emerging popularity of lentivirus gene therapy over conventional retroviral gene delivery systems owing to its several associated benefits, such as the ability to provide long-term and stable gene expression and to infect non-dividing cells, is also creating a positive outlook for the market. Besides this, the widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is bolstering the market growth. CFTRs are intended to regulate the flow of chloride and water through the cell linings of the lungs and rectify the malfunctioning protein in the body. Additionally, the ongoing development of personalized drug therapy, molecular prosthetics, and innovative drugs with improved efficacy is expected to drive the cystic fibrosis market in the coming years.

IMARC Group’s new report "Cystic Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Cystic Fibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Cystic Fibrosis market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Cystic Fibrosis across the seven major markets. According to the report the United States has the largest patient pool for Cystic Fibrosis and also represents the largest market for Cystic Fibrosis treatment. Furthermore, the current Cystic Fibrosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cystic Fibrosis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Cystic Fibrosis Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Cystic Fibrosis Market
Sales of Various Drugs Across the Cystic Fibrosis Market
Reimbursement Scenario in the Cystic Fibrosis Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Cystic Fibrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Cystic Fibrosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Cystic Fibrosis market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Cystic Fibrosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Cystic Fibrosis market?

Epidemiology Insights

What is the size of the Cystic Fibrosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Cystic Fibrosis across the seven major markets?
What are the key factors driving the epidemiological trend of Cystic Fibrosis?
What will be the growth rate of Cystic Fibrosis patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Cystic Fibrosis drugs and what are their market performance?
What are the key pipeline Cystic Fibrosis drugs and how are they expected to perform in the coming years?
How safe are the current marketed Cystic Fibrosis drugs and what are their efficacies?
How safe are the late-stage pipeline Cystic Fibrosis drugs and what are their efficacies?
What are the current treatment guidelines for Cystic Fibrosis drugs across the seven major markets?
Who are the key companies in the Cystic Fibrosis market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cystic Fibrosis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Cystic Fibrosis - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence

5 Cystic Fibrosis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Cystic Fibrosis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)

8 Cystic Fibrosis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Cystic Fibrosis Guidelines, Management and Treatment
8.2 Cystic Fibrosis Treatment Algorithm

9 Cystic Fibrosis - Unmet Needs

10 Cystic Fibrosis - Key Endpoints of Treatment

11 Cystic Fibrosis - Marketed Products
11.1 List of Cystic Fibrosis Marketed Drugs Across the Top 7 Markets
11.1.1 Elexacaftor - Vertex Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Kalydeco (Ivacaftor) - Vertex Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tezacaftor - Vertex Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Pulmozyme (Dornase Alfa) - Genentech
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.

12 Cystic Fibrosis - Pipeline Drugs
12.1 List of Cystic Fibrosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Tiotropium bromide - Boehringer Ingelheim
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Bamocaftor - Vertex Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Miglustat - Actelion Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Idrevloride - Parion Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Ensifentrine - Verona Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.

13. Cystic Fibrosis - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Cystic Fibrosis - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Cystic Fibrosis - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Cystic Fibrosis - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Cystic Fibrosis - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Cystic Fibrosis - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Cystic Fibrosis - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Cystic Fibrosis - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Cystic Fibrosis - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Cystic Fibrosis - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Cystic Fibrosis - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Cystic Fibrosis - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Cystic Fibrosis - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Cystic Fibrosis - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Cystic Fibrosis - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Cystic Fibrosis - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Cystic Fibrosis - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Cystic Fibrosis - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Cystic Fibrosis - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Cystic Fibrosis - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Cystic Fibrosis - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Cystic Fibrosis - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Cystic Fibrosis - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Cystic Fibrosis - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Cystic Fibrosis - Access and Reimbursement Overview

15 Cystic Fibrosis - Recent Events and Inputs From Key Opinion Leaders

16 Cystic Fibrosis Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix